Blog | HemaCare

Everything You Need to Know About Apheresis

Mar 27, 2017 12:41:11 PM / by Stacy Matthews Branch, DVM, PhD posted in apheresis, Innovation, leukemia, leukopaks

0 Comments

Many people have donated blood in their lifetime. This blood is not only used for transfusions, but to provide blood components to treat a number of diseases and to conduct research geared to develop new diagnostic and treatment strategies. To obtain specific blood components, the technique of apheresis is used. This procedure is the means to separate blood into its various components so that the desired one is removed. Then, the rest of the components are placed back into the donor’s circulation.

Read More

Getting personal with your cancer therapy

Aug 3, 2016 3:35:05 AM / by Stacy Matthews Branch, DVM, PhD posted in cancer, Cancer Immunology, cancer immunotherapy, cell therapy, clinical trial, Innovation

0 Comments

For many years, cancer therapy has been tackled with a more or less universal approach. The drawback of this approach to therapy is the wide range of different responses to a given therapy. The concept of personalized medicine, tailoring treatment to a patient’s specific characteristics, has been envisioned and desired for many years. It is now being studied and implemented to increase successful responses to therapy, including cancer therapy.

Read More

A New Therapy Against Tuberculosis: NOD-2 Derived Dendritic Cells

Jul 27, 2016 1:00:57 PM / by Dalia Gaddis posted in Bone marrow, infections, Innovation, intracellular pathogens, Lung, Mycobacterium, research, tuberculosis

0 Comments

Scientists find that NOD-2 derived dendritic cells have superior bactericidal activity.

Intracellular bacterial infections, such as tuberculosis, Listeria or E. coli, are serious health threats. All can be deadly if our immune system fails to contain and get rid of the infection promptly. Scientists have just found a way to make dendritic cells better at restricting the growth of intracellular bacteria, particularly tuberculosis.

Read More

Dendritic Cell Immunotherapy Gets a Boost

Jul 25, 2016 1:00:30 PM / by Steffen Porwollik posted in brain cancer, Cancer Immunology, cancer immunotherapy, cytotoxic T cells, Dendritic cells, glioma, immunogenic cell death, Innovation, T cells

0 Comments

A new strategy significantly increases the efficacy of dendritic cell immunotherapy against high grade glioma, a severe type of brain cancer. The key: pre-exposing the therapy to glioma cells undergoing immunogenic cell death.

High grade glioma (HGG) is a malignant brain cancer that is characterized by tumorous growth of glial cells, non-neural cells surrounding the neurons of the central and peripheral nervous system. HGG is accompanied by a heartbreakingly poor prognosis and the current lack of a cure. Hundreds of children are diagnosed every year with HGG in Europe and North America.

Read More

Differences Between Primary Cells and Cell Lines

Jul 20, 2016 3:29:50 PM / by Stacy Matthews Branch, DVM, PhD posted in cell therapy, Innovation, research

0 Comments

The following infographic discusses the differences between primary cells and cell lines.

Historically, cell lines have been useful research tools. However, they are subject to a number of inherent risks due to their altered or engineered nature, creating an "artificial cell-based system".

Read More

Subscribe Here!

Posts by Topic

see all

Recent Posts